comprehensive -WSS

comprehensive

author：Wikipedia 2025-09-30 08:52:30 - browse：46

Geoff Martha, CEO of Medtronic Courtesy Medtronic

As one of the largest and oldest medical device companies in the world, Medtronic has a foot in almost every clinical area.

The device maker with a market valuation of nearly $100 billion sells pacemakers, spinal cord stimulators, stents, monitors. Name a device, and they probably make it. The behemoth is ubiquitous in health care, but its size can make innovation sluggish. Medtronic has tried to become more streamlined in recent years — the company announced plans last year to spin off its patient monitoring and respiratory businesses, which Reuters recently reported, citing unnamed sources, may go to the Carlyle Group, a private equity firm.

Still, the device giant is immersed in many different specialties, including diabetes and high blood pressure, where the company has experienced some setbacks. Medtronic has sold old-school insulin pumps since the 1980s and therefore developed robust dosing algorithms, but has never successfully built a tubeless pump. The company plans to buy Korean patch pump maker EOFlow, but EOFlow is enmeshed in a patent battle with Insulet. A federal judge blocked EOFlow from selling its wearable patch pumps earlier this month.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： Study: Black kids more likely to die after surgery than white kids

WSS

A single drug, study failures leave Anavex with nothing but cash

Covid silver lining: Unprecedented look at human immune system

Study: Black kids more likely to die after surgery than white kids

Feng Zhang CRISPR delivery startup lays off quarter of staff

Insitro, AI biotech unicorn, brings cash, new research to JPM 2024

Federal weight loss drug coverage is 30 years out of date

explore

comprehensive

focus

New air purifier tech could be key to improving indoor air quality

UCB departs biotech trade group BIO

Malaria cases in Florida and Texas: Here’s what you need to know

At JPM, Bristol Myers Squibb CEO tries to soothe investor nerves

In age of alternative facts, a scholarly course on calling out crap

Antibiotic resistance and the global rise in human conflict

What does generative AI mean for health care? We asked experts

People with mental disorders often marry others with same

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Burning questions for the 2024 JPM Healthcare Conference

hotspot

Susan Tousi leaves Illumina to head cancer liquid biopsy startup

Drug companies' payments and gifts affect physicians' prescribing

Trial using CRISPR to edit HIV out of cells disappoints

Oral obesity drug from Viking Therapeutics hits key early target

Hundreds died while taking an arthritis drug, but nobody alerted patients

UnitedHealth, in a surprise, takes aim at Steward’s physician group

hotspot

hotspot

knowledge

entertainment